深部脑刺激与常规治疗对难治性强迫症的成本效果分析
该研究建立四个决策分析模型,比较深部脑刺激(DBS)与常规治疗(TAU)对难治性强迫症的成本效果,模型按设备类型(不可充电或可充电)和时间跨度(3年或5年)区分。基于文献的249例和265例患者数据,可充电DBS模型相比TAU具有成本效果,不可充电DBS模型可能具有成本效果。
要点
- 可充电DBS在3年和5年相比TAU均具有成本效果。
- 不可充电DBS模型在常规美国支付意愿阈值下成本效果较低。
- 在WHO支付意愿惯例下,不可充电和可充电DBS模型多数迭代中具有成本效果。
核心结论
- 可充电DBS模型相比TAU对难治性强迫症具有成本效果。
- 不可充电DBS模型可能具有成本效果,尤其当电池寿命改善和支付意愿阈值改变时。
研究设计与样本
- 研究建立四个决策分析模型,比较DBS与TAU对强迫症的成本效果,每个模型分别改变设备类型(不可充电或可充电)或时间跨度(3年或5年)。
- 治疗反应和并发症率基于文献综述,使用已发表算法将耶鲁-布朗强迫量表评分转换为反映生活质量改善的效用值。
- 成本从医疗保健部门视角估算,主要来自Medicare机构和医师报销费率。
- 每个模型进行蒙特卡洛模拟(n=100,000)和概率敏感性分析,估算每质量调整生命年(QALY)的增量成本效果比(ICER)。
主要发现
- 纳入文献中接受DBS且有足够随访的难治性强迫症患者数据,3年模型249例,5年模型265例。
- 采用常规美国支付意愿阈值时,不可充电DBS模型相比TAU成本效果较低(3年ICER:108,431美元/QALY;5年ICER:203,202美元/QALY)。
- 采用常规美国支付意愿阈值时,可充电DBS模型相比TAU成本效果较高(3年ICER:49,363美元/QALY;5年ICER:41,495美元/QALY)。
- 在支付意愿阈值100,000美元/QALY下,可充电DBS设备在3年和5年相比TAU在100%迭代中具有中等成本效果。
- 在支付意愿阈值50,000美元/QALY下,可充电DBS设备在3年和5年相比TAU分别在54%和89%迭代中明确具有成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Deep brain stimulation (DBS) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (OCD). Despite being more costly than neuroablative procedures of comparable efficacy, DBS has gained popularity over the years for its reversibility and adjustability. Although the cost-effectiveness of DBS has been investigated extensively in movement disorders, few economic analyses of DBS for psychiatric disorders exist. In this study, the authors present the first cost-effectiveness analysis of DBS for treatment-resistant OCD in the United States. METHODS: The authors developed four decision analytical models to compare the cost-effectiveness of DBS with treatment as usual (TAU) for OCD, varying either the device type (i.e., nonrechargeable or rechargeable) or the time horizon (i.e., 3 or 5 years) in each model. Treatment response and complication rates were based on a literature review. Published algorithms were used to convert Yale-Brown Obsessive Compulsive Scale scores into utility scores reflecting improvements in quality of life. Costs were approached from the healthcare sector perspective and were drawn primarily from Medicare facility and physician reimbursement rates. For each model, a Monte Carlo simulation (n = 100,000) and probabilistic sensitivity analysis were performed to estimate the incremental cost-effectiveness ratio (ICER) in US dollars per quality-adjusted life year (QALY). RESULTS: Data from 249 and 265 treatment-resistant OCD patients from the published literature who received DBS and had sufficient follow-up in 3- and 5-year models, respectively, were included. When conventional US willingness-to-pay (WTP) thresholds were used, nonrechargeable DBS models were less cost-effective (3-year ICER: $108,431/QALY; 5-year ICER: $203,202/QALY) and rechargeable DBS models were more cost-effective (3-year ICER: $49,363/QALY; 5-year ICER: $41,495/QALY) than TAU. At a WTP threshold of $100,000/QALY, rechargeable DBS devices were moderately more cost-effective than TAU at 3 and 5 years in 100% of iterations. At a WTP threshold of $50,000/QALY, rechargeable DBS devices were definitively more cost-effective than TAU at 3 and 5 years in 54% and 89% of iterations, respectively. When using WHO WTP conventions, 3- and 5-year nonrechargeable models were cost-effective in 100% and 84% of iterations, and 3- and 5-year rechargeable models were highly cost-effective in 99% and 100% of iterations, respectively. CONCLUSIONS: Rechargeable DBS models were cost-effective for treatment-resistant OCD compared with TAU. Nonrechargeable DBS models may be cost-effective, especially with improvement in battery longevity and changes in accepted WTP thresholds.
引用
- Najera RA, Kabotyanski KE, McLaughlin NC, et al. Cost-effectiveness analysis of deep brain stimulation versus treatment as usual for treatment-resistant obsessive-compulsive disorder. J Neurosurg. 2025. PMID: 39752646. doi:10.3171/2024.7.JNS232642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。